Abstract |
Killer immunoglobulin-like receptors (KIRs) regulate cell activity of natural killer (NK) cells and some T cells. The predominant ligand for inhibitory KIRs is HLA-C, which subdivides into 2 groups based on the specificity of inhibitory KIRs. The ligands for activatory KIRs are unknown. Following hematopoietic stem cell transplantation (HSCT), recipient tissues may not express a ligand for KIRs present within the graft, and the combination of donor KIR and recipient HLA-C types could influence outcome. HLA and KIR genotypes were determined in 220 donor-recipient pairs from HLA-matched sibling HSCTs performed for myeloid (n = 112) and lymphoid (n = 108) diseases. In HSCTs performed for myeloid disease, overall survival was worse in patients homozygous for group 2 HLA-C (C2) than in patients who carried a group 1 HLA-C (C1) allele (P <.005). Moreover, this effect is seen only when the donor additionally carries the activating KIR gene KIR2DS2 (P =.045). No effect was seen in patients with lymphoid disease. Thus, in HLA-matched sibling HSCT for myeloid leukemia, patients homozygous for C2 alleles receiving a graft from a donor carrying the KIR gene KIR2DS2 have a significantly reduced chance of survival.
|
Authors | Mark A Cook, Donald W Milligan, Christopher D Fegan, Philip J Darbyshire, Premini Mahendra, Charles F Craddock, Paul A H Moss, David C Briggs |
Journal | Blood
(Blood)
Vol. 103
Issue 4
Pg. 1521-6
(Feb 15 2004)
ISSN: 0006-4971 [Print] United States |
PMID | 14504099
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- HLA-C Antigens
- Receptors, Immunologic
- Receptors, KIR
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Female
- Genotype
- HLA-C Antigens
(genetics)
- Hematopoietic Stem Cell Transplantation
- Histocompatibility Testing
- Humans
- Leukemia, Myeloid
(genetics, mortality, therapy)
- Male
- Middle Aged
- Receptors, Immunologic
(genetics)
- Receptors, KIR
- Survival Analysis
- Treatment Outcome
|